Loading...

BIO-PATH HOLDINGS INC US FDA Inspections 8-K Filing

B-PT

BIO-PATH HOLDINGS INC

()

2024 8-K

Company Updates

Control Changes

Management Changes

Leadership Changes

Accountant Dismissal

Product Expansion

Debt-Equity Swaps

Securities Agreement

Financial Results

Product Announcement

Securities Agreement

Stock Delisting

Clinical Update

New Treatment Testing

Nasdaq Compliance Notice

Treatment Development

Nasdaq Listing Update

Financial Results

Private Placement

Nasdaq Delisting Risk

Patient Response Update

Financial Results

Phase 2 Study Data Presenta...

Securities Purchase Agreement

Data Presentation at ASCO A...

Earnings Reports

Increase in At The Market O...

Entry Into a Material Defin...

Clinical Trial Update

Expanding Patent Portfolio

Agreement for Stock Sale

Securities Purchase Agreement

Compliance Regained

Reverse Stock Split

Special Meeting Vote

Special Meeting

Clinical Trial Update

Clinical Trial Completion

Bylaws Amendment

Earnings Report

Earnings Reports

Clinical Trial Results

Clinical Trial Completion

Earnings Report

Earnings Report

External Links:

Bio-Path Holdings, Inc. announced its rationale for developing BP1001-A as a potential treatment for obesity in Type 2 diabetes patients through a press release on December 11, 2024.

AI Assistant

BIO-PATH HOLDINGS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.